Numerous peer reviewed, scientific publications have shown its importance in human physiology as a modulator of cardiovascular, gastrointestinal, and immune function, metastatic transformation and key aspects of central nervous system function, including movement disorders, pain, and behavior. The ECS is therefore an attractive and validated target for pharmacological intervention.
Artelo’s business model is to develop multiple pharmacological approaches to ECS modulation. Candidate therapeutic compounds within our current portfolio are based on targeting cannabinoid receptors and endocannabinoid transport inhibition.
Modulating the ECS shows vast promise to relieve an array of symptoms, including pain, nausea, anxiety, sleeplessness, decreased appetite, and inflammation. The clinical use of cannabinoids is probably best known in multiple sclerosis and nausea associated with cancer, and there are several pharmaceutical products that modulate the ECS already available in many countries.